You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

NICE approves Merck’s Keytruda for adult patients with rare triple negative breast cancer

Merck & Co – known as MSD outside the US and Canada – has received a recommendation from The National Institute for Health and Care Excellence (NICE) for its new injectable treatment, Keytruda, with chemotherapy in adults with a rare form of triple negative breast cancer.